The ‘Handbook of Translational Medicine’ is available now. Edited by Prof Josep M Llovet in collaboration with other teachers from the official Master in Translational Medicine (University of Barcelona).
Prof Llovet has been elected Vice-Chair of the AASLD Hepatobiliary Neoplasia SIG. His 2 year term will begin on January 1st, 2017 until December 31st, 2018 and then he will move into the Chair role for 2 years beginning January 1st, 2019 until December 31st, 2020.
In the study, published in the Gastroenterology journal, they have found that this alteration occurs in 15% of tumors and that a monoclonal antibody can effectively block it and slow tumor progression in animal models. Dr. Josep M. Llovet, ICREA Professor, Head of the Translational research in hepatic oncology IDIBAPS group and Director of the Mount Sinai Liver Cancer Program at Icahn School of Medicine at Mount Sinai (New York), has coordinated this study. The first authors of the article are Iris Martínez-Quetglas and Roser Pinyol, researchers at the same team.
Thomson Reuters lists the 3000 most important names of 21 fields in science and social sciences. There have been evaluated articles published in indexed journals in these fields between 2003 and 2013 and there have only been considered those that rank in the top 1% by citations for field and year indexed in the Web of Science, the so called Highly Cited Papers. Thus, the fact of belonging to this classification means that the work of these researchers is considered particularly important among his colleagues.
The Translational Reserarch in Hepatic Oncology IDIBAPS group, led by Dr. Josep M. Llovet, in collaboration with Dr. Roser Pinyol and 8 more researchers, participates in a European project to identify the molecular mechanisms that have a direct impact on the development of hepatocellular carcinoma (HCC). The HEP-CAR project will evaluate the role of these mechanisms in different liver diseases leading to HCC -the infection by hepatitis B and C, overweight or alcohol-. This research initiative, coordinated by the University of Freiburg and in which ten European academic centers are involved, is part of Horizon 2020, the European Comission framework programme for research and innovation, and it is endowed with a budget of 5.7 million euros, one of them corresponding to IDIBAPS.
IDIBAPS researchers have participated in a pioneering study in hepatocellular carcinoma, the most common liver cancer, in which all the genetic alterations that occur in this type of tumor have been characterized. In an article published in the journal Nature Genetics scientists provide a complete overview of the disease and these genetic alterations associated with the etiology and clinical characteristics, the proposed treatments for patients approved for other cancers, which could be applied in each case. Dr. Josep Maria Llovet, ICREA professor at the IDIBAPS Hepatic Oncology Group and director of the Liver Cancer Program at the Icahn School of Medicine at Mount Sinai (New York), and Dr. Roser Pinyol, researcher at the same group, have participated in this article led by Dr. Jessica Zucman-Rossi, from the INSERM-Paris.
El colangiocarcinoma hepático, una de las clases de cáncer de hígado más agresiva, ya no es un tumor desconocido. Un grupo de investigadores de 16 profesionales del Instituto de Investigaciones Biomédicas Pi i Sunyer, centro adscrito al hospital Clínic en Barcelona, han establecido su composición molecular.
Thomson Reuters has published the list of the Highly Cited Researchers, a compilation of the most influential names in science. 50 Spanish researchers from different broad fields of sciences and social sciences appear on the list. In the field of Clinical Medicine, four of the seven Spanish investigators listed are researchers from IDIBAPS. The health research institute associated to Hospital Clínic and Universitat de Barcelona also has the only Spanish researcher in Psychiatry.
DIBAPS participates in 10 of the 50 most influential works of the last 10 years with Spanish participation The Centre for Research Survey of the Institute of Catalan Studies (Observatori de la Recerca de l’Institut d’Estudis Catalans)publishes almost half of the most cited researchers in Spain work in Catalonia. IDIBAPS is, with 10 articles, the Catalan center which appears in a greater number of jobs among the 50 most cited papers with Spanish participation. These data confirm once again the significance of Catalan research and IDIBAPS, Hospital Clinic of Barcelona Faculty of Medicine and University of Barcelona leadership. The data were extracted from Thomson Reuters Essential Science Indicators database, which determines from bibliometric data the influence of researchers, institutions, documents, publications, scientific fields and emerging research areas in 22 countries. Among the 50 documents participated by institutions in Spain collecting a greater number of citations, 36 (72%) have at least one author from geographical areas of Catalan language and culture. In addition, 47.4% of the 78 Spanish researchers involved work in scientific institutions in Catalonia.
The Journal of Hepatology is the official journal of the European Association for the Study of the Liver (EASL), and a key resource in the specialty. With each issue this Journal publishes original papers, reviews, case reports and letters to the Editor concerned with clinical and basic research in the field of hepatology.
Dr. Jordi Bruix and Dr. Josep Maria Llovet receive the International Hans Popper Award
Every year the United European Gastroenterology (UEG) National Societies Committee and the Scientific Committee jointly select up to 10 emerging clinical scientists. In the 2013 edition of the Rising Star awards two IDIBAPS investigators are among the winners: Dr.Augusto Villanueva, from the IDIBAPS Hepatocellular Carcinoma Translational Research Lab (BCLC group), and Dr. Francesc Balaguer, from the IDIBAPS Gastrointestinal and Pancreatic Oncology team. The awarded researchers are young and highly qualified professionals from around Europe with a relevant international-quality research. This initiative provides a durable platform for young researchers so that they can give state-of-the-art lectures and chair scientific sessions at UEG Week. The next one will take place on October 12-16, in Berlin.
Less than 30% of newly diagnosed hepatocellular carcinoma (HCC) patients are eligible for curative therapies such as resection, liver transplantation, or local ablation. Hence, there is an increasing need to develop new drugs for a disease that, besides being the third leading cause of cancer death worldwide, has tripled its incidence in the last decades in the United States. An article published in Gastroenterology by the IDIBAPS Translational Research in Hepatic Oncology group, led by the ICREA investigator Prof Josep Maria Llovet, demonstrates that Notch signaling is activated in a subset of human HCC samples, and promotes liver tumor formation in genetically engineered mice. In addition, the study reports a Notch gene signature able to predict response to Notch inhibition in experimental models of liver cancer. First authorship of the manuscript is shared by Dr Augusto Villanueva and Clara Alsinet. The study is the result of an international collaboration that includes renown leaders in the field from the University of Pennsylvania (Philadelphia), the Broad Institute and Dana-Farber Cancer Institute at Harvard Medical School (Boston), and Mount Sinai School of Medicine (New York).
Prof Llovet was invited to participate as speaker at the EU Grant Session: “Improving Liver Research Funding from the EU” which was held on Friday, April 1, 2011 during the International Liver Congress by EASL in Berlin, Germany from March 30th – April 3rd, 2011. This new initiative aimed to promote and exchange the numerous programmes, projects and support that are carried out at EU level. Prof Llovet gave a talk that presented his experience as Principal Investigator within a European project and explained how is the Heptromic Project the first European Research project centred specifically on the genomics of this type of cancer.
The HEPTROMIC video was presented during the kick-off meeting of the Project, which took place yesterday in Barcelona. Its main objective is to explain the goals and the project and the outstanding team that will make it possible.
HEPTROMIC is the first research network funded by the European Commission devoted to the study of Hepatocellular Carcinoma (HCC). It is a 3-year translational research project which aims to solve core problems in the management of HCC, the third most common cause of cancer-related death worldwide. The partners taking part in this initiative have met today in Barcelona in the called kick-off meeting, which officially starts the project. Dr. Josep Maria Llovet, ICREA Research professor at IDIBAPS - Hospital Clínic, and his team lead that project which is meant to change the treatment of this cancer in the next years.